Prognostic factors in Waldenstrom's macroglobulinemia: Description of the complications during the evolution—preliminary results on 101 patients

Stalnikiewicz, Laure; Carrotte-Lefebvre, I.; Detourmignies, Laurence; Rose, Christian; Cazin, Bruno; Leblond, Véronique; Morel, Pierre

doi:10.1053/sonc.2003.50076

Cited by 10 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have reported the occurrence of transformation to high-grade lymphoma in approximately 2% of patients [4,71,72] and the occurrence of solid tumors in 10-14% of patients during follow-up of patients with WM [4,5,72,73] or even before diagnosis [5]. Cumulative incidence of solid cancer and secondary malignancy have been estimated to be 17 and 8% at 15 years, respectively, with an overall risk of secondary cancer in WM 1.69 times higher than expected (p = 0.002).…”

Section: Assessment Of the Risk Of Late Complicationsmentioning

confidence: 99%

Risk stratification in Waldenström macroglobulinemia

Morel¹,

Merlini

2012

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

Section: Assessment Of the Risk Of Late Complicationsmentioning

confidence: 99%

Risk stratification in Waldenström macroglobulinemia

Morel¹,

Merlini

2012

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

“…[1][2][3] Clinical features of WM are due to either infiltration of neoplastic cells or properties of the circulating IgM. [1][2][3][4][5][6] Proliferation of neoplastic cells is associated with the prognosis for long term survival and many systemic features of WM, including cytopenia, lymphadenopathy, splenomegaly, and hepatomegaly. Disorders related to the circulating IgM often cause considerable morbidity [5][6][7][8] and include amyloidosis, polyneuropathies, and disorders related to hyperviscosity, cryoglobulinaemia, and cold agglutinin.…”

mentioning

confidence: 99%

Peripheral neuropathies in Waldenstrom's macroglobulinaemia

Levine

Pestronk

Florence

et al. 2006

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

Objective: We sought to determine the prevalence, clinical features, and laboratory characteristics of polyneuropathies in Waldenström's macroglobulinaemia (WM), a malignant bone marrow disorder with lymphocytes that produce monoclonal IgM. Methods: We prospectively studied 119 patients with WM and 58 controls. Medical history was taken, and neurological examinations, electrodiagnostic tests, and serum studies were performed by different examiners who were blinded to results except the diagnosis of WM. Results: Polyneuropathy symptoms, including discomfort and sensory loss in the legs, occurred more frequently (p,0.001) in patients with WM (47%) than in controls (9%). Patients with WM had 35% lower quantitative vibration scores, and more frequent pin loss (3.4 times) and gait disorders (5.5 times) than controls (all p,0.001). Patients with IgM binding to sulphatide (5% of WM) had sensory axon loss; those with IgM binding to myelin associated glycoprotein (MAG) (4% of WM) had sensorimotor axon loss and demyelination. Patients with WM with IgM binding to sulphatide (p,0.005) or MAG (p,0.001) had more severe sensory axon loss than other patients with WM. Demyelination occurred in 4% of patients with WM with no IgM binding to MAG. Age related reductions in vibration sense and sural SNAP amplitudes were similar (,30%) in WM and controls. Conclusions: Peripheral nerve symptoms and signs occur more frequently in patients with WM than controls, involve sensory modalities, and are often associated with gait disorders. IgM binding to MAG or sulphatide is associated with a further increase in the frequency and severity of peripheral nerve involvement. Age related changes, similar to those in controls, add to the degree of reduced nerve function in patients with WM.

show abstract

“…Most studies have focused on overall survival from diagnosis to last follow-up, but others have analyzed survival after initiation of treatment in patients with symptomatic WM (Gobbi et al 1994 ;Dhodapkar et al 2001 ). Preliminary results pointed to the high incidence of long-lasting monoclonal component during the course of WM and the low frequency (6 %) of patients who experienced a rapid rise of the monoclonal component (Stalnikiewicz et al 2003 ). As previously underlines in epidemiology section, some series have shown a high incidence of cancer.…”

Section: Molecular Geneticsmentioning

confidence: 62%

Rare Lymphomas

2014

View full text Add to dashboard Cite

Prognostic factors in Waldenstrom's macroglobulinemia: Description of the complications during the evolution—preliminary results on 101 patients

Cited by 10 publications

References 14 publications

Risk stratification in Waldenström macroglobulinemia

Risk stratification in Waldenström macroglobulinemia

Peripheral neuropathies in Waldenstrom's macroglobulinaemia

Rare Lymphomas

Contact Info

Product

Resources

About